Literature DB >> 22778874

Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Susanne Koschatzky1, Nuska Tschammer, Peter Gmeiner.   

Abstract

Dopaminergic systems have been described to functionally interact with the neuromodulatory peptide neurotensin. Employing fluorescence detected coimmunoprecipitation and radioligand binding experiments, we herein demonstrate that coexpression of dopamine D(2L) receptor and the neurotensin receptor subtype NTS(1) leads to physical interaction and the formation of heteromers in transfected human embryonic kidney 293 cells. In this in vitro system, a trans-inhibitory effect on the agonist binding affinity of D(2) was observed in presence of neurotensin. To correlate between the functional properties of dopaminergic agents and the magnitude of neurotensin-induced modulation of D(2L) binding affinities in cells coexpressing D(2L) and NTS(1), a structurally diverse set of dopamine receptor agonists, partial agonists, and antagonists was tested. Ligand specific profiles indicating substantial bias between ligand efficacy and transmodulation were discovered, suggesting a heteromerization-based functional selectivity. In the presence of neurotensin, the novel D(2) agonist FAUC 326 displayed a 34-fold decrease of binding affinity in cells coexpressing D(2L) and NTS(1).

Entities:  

Keywords:  Dopamine D2L receptor; G-protein coupled receptor; GPCR; NTS1; binding affinity; coexpression; coimmunoprecipitation; dimer; heteromer; intramembrane receptor−receptor interaction; negative cooperativity; neurotensin receptor 1

Mesh:

Substances:

Year:  2011        PMID: 22778874      PMCID: PMC3369761          DOI: 10.1021/cn200020y

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  51 in total

1.  Neurotensin reduces the affinity of D-2 dopamine receptors in rat striatal membranes.

Authors:  G Von Euler; K Fuxe
Journal:  Acta Physiol Scand       Date:  1987-12

2.  Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.

Authors:  L F Agnati; K Fuxe; F Benfenati; N Battistini
Journal:  Acta Physiol Scand       Date:  1983-12

3.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

4.  Neurotensin reduces the affinity of dopamine D2 receptors in membranes from post mortem human caudate-putamen.

Authors:  G von Euler; P Mailleux; J J Vanderhaeghen; K Fuxe
Journal:  Neurosci Lett       Date:  1990-02-16       Impact factor: 3.046

5.  Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene.

Authors:  J G Cannon; J A Perez; J P Pease; J P Long; J R Flynn; D B Rusterholz; S E Dryer
Journal:  J Med Chem       Date:  1980-07       Impact factor: 7.446

6.  Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor.

Authors:  D Gully; M Canton; R Boigegrain; F Jeanjean; J C Molimard; M Poncelet; C Gueudet; M Heaulme; R Leyris; A Brouard
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

7.  Intraventricular injection of neurotensin reduces dopamine D2 agonist binding in rat forebrain and intermediate lobe of the pituitary gland. Relationship to serum hormone levels and nerve terminal coexistence.

Authors:  G von Euler; B Meister; T Hökfelt; P Eneroth; K Fuxe
Journal:  Brain Res       Date:  1990-10-29       Impact factor: 3.252

8.  Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum.

Authors:  S Tanganelli; X M Li; L Ferraro; G Von Euler; W T O'Connor; C Bianchi; L Beani; K Fuxe
Journal:  Eur J Pharmacol       Date:  1993-01-12       Impact factor: 4.432

9.  Neurotensin modulates the binding characteristics of dopamine D2 receptors in rat striatal membranes also following treatment with toluene.

Authors:  G von Euler; K Fuxe; F Benfenati; T Hansson; L F Agnati; J A Gustafsson
Journal:  Acta Physiol Scand       Date:  1989-04

10.  Biochemical characterization of the intramembrane interaction between neurotensin and dopamine D2 receptors in the rat brain.

Authors:  G von Euler
Journal:  Brain Res       Date:  1991-10-04       Impact factor: 3.252

View more
  11 in total

Review 1.  Dopamine D2 autoreceptor interactome: Targeting the receptor complex as a strategy for treatment of substance use disorder.

Authors:  Rong Chen; Mark J Ferris; Shiyu Wang
Journal:  Pharmacol Ther       Date:  2020-05-27       Impact factor: 12.310

Review 2.  Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse.

Authors:  Ivone Gomes; Wakako Fujita; Moraje V Chandrakala; Lakshmi A Devi
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

3.  Activation of neurotensin receptor type 1 attenuates locomotor activity.

Authors:  Chelsea A Vadnie; David J Hinton; Sun Choi; YuBin Choi; Christina L Ruby; Alfredo Oliveros; Miguel L Prieto; Jun Hyun Park; Doo-Sup Choi
Journal:  Neuropharmacology       Date:  2014-06-11       Impact factor: 5.250

4.  Neurotensin inhibits both dopamine- and GABA-mediated inhibition of ventral tegmental area dopamine neurons.

Authors:  Katherine Stuhrman; Aaron G Roseberry
Journal:  J Neurophysiol       Date:  2015-07-15       Impact factor: 2.714

Review 5.  Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization.

Authors:  Kjell Fuxe; Alexander Tarakanov; Wilber Romero Fernandez; Luca Ferraro; Sergio Tanganelli; Malgorzata Filip; Luigi F Agnati; Pere Garriga; Zaida Diaz-Cabiale; Dasiel O Borroto-Escuela
Journal:  Front Endocrinol (Lausanne)       Date:  2014-05-13       Impact factor: 5.555

Review 6.  Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders.

Authors:  Chelsea A Vadnie; Jun Hyun Park; Noha Abdel Gawad; Ada Man Choi Ho; David J Hinton; Doo-Sup Choi
Journal:  Front Neurosci       Date:  2014-09-18       Impact factor: 4.677

Review 7.  Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease.

Authors:  Dasiel O Borroto-Escuela; Jens Carlsson; Patricia Ambrogini; Manuel Narváez; Karolina Wydra; Alexander O Tarakanov; Xiang Li; Carmelo Millón; Luca Ferraro; Riccardo Cuppini; Sergio Tanganelli; Fang Liu; Malgorzata Filip; Zaida Diaz-Cabiale; Kjell Fuxe
Journal:  Front Cell Neurosci       Date:  2017-02-21       Impact factor: 5.505

8.  Differential allosteric modulation within dopamine D2R - neurotensin NTS1R and D2R - serotonin 5-HT2AR receptor complexes gives bias to intracellular calcium signalling.

Authors:  Michael Plach; Thorsten Schäfer; Dasiel Oscar Borroto-Escuela; Dorothée Weikert; Peter Gmeiner; Kjell Fuxe; Kristina Friedland
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

9.  Structure-guided development of heterodimer-selective GPCR ligands.

Authors:  Harald Hübner; Tamara Schellhorn; Marie Gienger; Carolin Schaab; Jonas Kaindl; Laurin Leeb; Timothy Clark; Dorothee Möller; Peter Gmeiner
Journal:  Nat Commun       Date:  2016-07-26       Impact factor: 14.919

Review 10.  Brain Dopamine Transmission in Health and Parkinson's Disease: Modulation of Synaptic Transmission and Plasticity Through Volume Transmission and Dopamine Heteroreceptors.

Authors:  Dasiel O Borroto-Escuela; Miguel Perez De La Mora; Paul Manger; Manuel Narváez; Sarah Beggiato; Minerva Crespo-Ramírez; Gemma Navarro; Karolina Wydra; Zaida Díaz-Cabiale; Alicia Rivera; Luca Ferraro; Sergio Tanganelli; Małgorzata Filip; Rafael Franco; Kjell Fuxe
Journal:  Front Synaptic Neurosci       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.